In addition, survival analyses showed that ccRCC patients with increased NOP2 expression had poorer OS (Supplementary Fig. S1A), progression-free survival (PFS) (Supplementary Fig. S1B), and disease-specific survival (DSS) (Supplementary Fig. S1C). The gene discussed is NOP2; the disease is nonpapillary renal cell carcinoma.